Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

JAK inhibitors may effectively treat lichen planopilaris and frontal fibrosing alopecia with minimal side effects.

Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.

Infliximab was effective in treating a scalp condition that did not respond to other treatments.

All four treatments for early rheumatoid arthritis had similar and mostly mild side effects.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

RXRα is crucial for proper immune response and links diet to immune function.

An antibiotic called co-trimoxazole can effectively treat autoimmune diseases.

PRP shows promise for spinal pain but needs more guidelines before widespread use.

Topical Ruxolitinib may safely treat severe hair loss.

The new skin patch with human matrix and antibiotic improves wound healing.

Etanercept may not prevent alopecia areata from coming back.

Platelet-rich Plasma Gel may help treat en coup de sabre scleroderma, improving symptoms and skin quality with minimal side effects.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

CRISPR/Cas9 and prime editing can potentially fix skin disorder genes safely and effectively.

Platelet-rich fibrin helps in healing and rejuvenation but results vary and can take time.

High-dose mizoribine effectively controls symptoms in adolescents with lupus while reducing steroid use, with manageable side effects.

Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.

Low-dose naltrexone may help reduce redness in certain scalp conditions.

JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

The treatment was effective for advanced non-Hodgkin's lymphomas.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.